Want to see TSE:BBM full AI Analyst Report?
Blueberries Medical (BBM) AI Stock Analysis
Blueberries Medical
(CNQX:BBM)
The overall score of 43 reflects a high-risk, early-stage company with a fragile financial foundation. The most significant factor is the company's deeply unprofitable operations and declining revenue, which are rapidly consuming its equity. The primary strength is the improving operational efficiency, seen in better gross margins and a reduced cash burn rate, but this has not yet translated into financial stability. Technicals are neutral, and the negative P/E ratio underscores the speculative nature of the stock.
Blueberries Medical (BBM) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 4.47M
- Dividend Yield
- ―
- Average Volume (3M)
- 61.33K
- Price to Earnings (P/E)
- -7.1
- Beta (1Y)
- -2.21
- Revenue Growth
- -36.67%
- EPS Growth
- 40.54%
- Country
- Canada
- Employees
- 51
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Blueberries Medical Business Overview & Revenue Model
Company Description
Headquartered in Bogotá, Colombia, Blueberries Medical Corp. operates within the medicinal cannabis industry. The company's activities encompass the entire process, from cultivating and developing to producing and supplying medical-grade cannabis and...
Blueberries Medical Financial Statement Overview
Summary
Financial performance is weak, driven by persistent and deep net losses (-384% margin) and declining TTM revenue (-7.2%). While gross margin improvement (36.9%) and a sharply reduced cash burn rate (-45.6% FCF improvement) are positive signals of operational efficiency, the company remains pre-revenue stage with a rapidly eroding equity base (ROE -332%). The balance sheet is stable post-deleveraging (D/E 0.29x) but on a declining trajectory.
Income Statement
18Very NegativeBalance Sheet
55NeutralCash Flow
35Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 278.21K | 312.29K | 471.41K | 288.27K | 235.45K | 138.75K |
| Gross Profit | 102.20K | 49.50K | 164.52K | 84.22K | -17.72K | -245.45K |
| EBITDA | -695.46K | -1.28M | -1.04M | -1.22M | -811.47K | -4.05M |
| Net Income | -1.07M | -1.67M | -1.15M | -1.64M | -1.47M | -5.15M |
Balance Sheet | ||||||
| Total Assets | 670.10K | 679.62K | 1.38M | 2.42M | 3.35M | 3.59M |
| Cash, Cash Equivalents and Short-Term Investments | 14.77K | 26.39K | 66.08K | 818.16K | 1.41M | 1.34M |
| Total Debt | 8,282 | 137.88K | 11.44K | 12.80K | 1.34M | 1.44M |
| Total Liabilities | 641.44K | 358.45K | 545.61K | 470.72K | 1.89M | 2.16M |
| Stockholders Equity | 28.66K | 321.17K | 834.81K | 1.95M | 1.47M | 1.43M |
Cash Flow | ||||||
| Free Cash Flow | -607.78K | -1.24M | -796.85K | -1.35M | -1.47M | -1.73M |
| Operating Cash Flow | -607.78K | -1.24M | -796.85K | -1.33M | -1.47M | -1.68M |
| Investing Cash Flow | 0 | 0 | 9,003 | 382.92K | 101.94K | -48.77K |
| Financing Cash Flow | 394.76K | 1.18M | -1,947 | 539.10K | 1.35M | 2.77M |
Blueberries Medical Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BBM, the sentiment is Positive. The current price of 0.01 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.01, and above the 200-day MA of 0.01, indicating a bullish trend. The MACD of 0.00 indicates Negative momentum. The RSI at 51.88 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BBM.
Blueberries Medical Peers Comparison
Overall Rating
- TSE:BBM43Neutral
TSE:CDVA40.9Neutral
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:BBM | Blueberries Medical | 0.01 | -0.01 | -25.00% | |
| TSE:BAMM | Body & Mind | 0.03 | 0.00 | 0.00% | |
| TSE:CDVA | CordovaCann Corp | 0.03 | -0.00 | -16.67% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026